Department of Pathology, Northwestern University, Feinberg School of Medicine, 303 E Chicago Ave, Chicago, IL 60612, USA.
J Genet Genomics. 2013 Jul 20;40(7):347-54. doi: 10.1016/j.jgg.2013.04.001. Epub 2013 Apr 12.
Rheumatoid arthritis (RA) is a chronic debilitating disease of the joints. Both the innate and adaptive immune responses participate in the development and progression of RA. While several therapeutic reagents, such as TNF-α agonists, have been successfully developed for the clinical use in the treatment of RA, more than half of the patients do not respond to anti-TNF therapy. Therefore, new therapeutic reagents are needed. Recent studies have shown that sirtuin 1 (Sirt1), a nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase, is a critical negative regulator of both the innate and adaptive immune response in mice, and its altered functions are likely to be involved in autoimmune diseases. Small molecules that modulate Sirt1 functions are potential therapeutic reagents for autoimmune inflammatory diseases. This review highlights the role of Sirt1 in immune regulation and RA.
类风湿关节炎（RA）是一种慢性关节致残性疾病。先天免疫和适应性免疫反应都参与了 RA 的发生和发展。虽然已经成功开发了几种治疗试剂，如 TNF-α 激动剂，用于治疗 RA 的临床应用，但仍有超过一半的患者对 TNF 治疗无反应。因此，需要新的治疗试剂。最近的研究表明，烟酰胺腺嘌呤二核苷酸（NAD）依赖性组蛋白去乙酰化酶 Sirtuin 1（Sirt1）是小鼠先天免疫和适应性免疫反应的关键负调控因子，其功能改变可能与自身免疫性疾病有关。调节 Sirt1 功能的小分子可能是自身免疫性炎症性疾病的潜在治疗试剂。本文综述了 Sirt1 在免疫调节和 RA 中的作用。
